Shots: The P-III RATIONALE 309 study involves assessing tislelizumab + gemcitabine + cisplatin vs PBO combined with gemcitabine + cisplatin as a 1L treatment in 263 patients in a ratio […]readmore
Tags : Recurrent
Shots: The EC has granted conditional approval for Jemperli in women with dMMR/ MSI-H endometrial cancer that has progressed on or following prior treatment with a Pt.- containing regimen AnaptysBio […]readmore
Shots: The approval is based on the P-III NAVIGATE trial in adult and adolescent patients and P- I/II pediatric SCOUT trial involves assessing Vitrakvi for NTRK fusion-positive advanced or recurrent […]readmore
Shots: NMPA has granted BTD to socazolimab for cervical cancer. Socazolimab is licensed from Sorrento to COF for the greater China territory Lee intends to file an NDA to the […]readmore
Shots: The approval is based on P-II KEYNOTE-629 study assessing Keytruda (200mg, IV, q3w) in 105 patients with recurrent or metastatic cSCC that is not curable by surgery or radiation […]readmore
Shots: The approval is based on P-III CHANGE II study assessing extreme regimen (ERBITUX + cisplatin + 5-FU, followed by ERBITUX as maintenance therapy) vs Pt. based CT (cisplatin + […]readmore
Shots: Zejula (niraparib) is an oral once-daily poly (ADP-ribose) polymerase (PARP) inhibitor used as a maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, […]readmore
Shots: The EC has approved two regimens of Keytruda (monothx. and in combination with platinum and 5-fluorouracil (5-FU) CT), based on P-III KEYNOTE-048 study evaluating Keytruda vs SoC (cetuximab with […]readmore
Shots: The approval is based on two studies, KEYNOTE-181 study results involve assessing of Keytruda (200mg, q3w) vs CT (paclitaxel/docetaxel) in 628 patients in a ratio (1:1) with 1L+ LA/m- […]readmore
Shots: The approval is based on P-II STARTRK-2, P-I STARTRK-1, P-I ALKA-372-001 & P-I/II STARTRK-NG studies results assessing Rozlytrek in adults & pediatric patients with NTRK fusion-positive solid tumors, across […]readmore